COSCIENS Operating Cycle from 2010 to 2026

CSCI Stock   2.68  0.03  1.11%   
COSCIENS Biopharma's Operating Cycle is decreasing with slightly volatile movements from year to year. Operating Cycle is predicted to flatten to 194.27. For the period between 2010 and 2026, COSCIENS Biopharma, Operating Cycle quarterly trend regression had mean deviation of  166.12 and range of 1.5 K. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
236.98
Current Value
194.27
Quarterly Volatility
339.94365599
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check COSCIENS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among COSCIENS Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 99.3 K or Total Revenue of 16.6 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 0.59. COSCIENS financial statements analysis is a perfect complement when working with COSCIENS Biopharma Valuation or Volatility modules.
  
Build AI portfolio with COSCIENS Stock
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
The Operating Cycle trend for COSCIENS Biopharma offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether COSCIENS Biopharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest COSCIENS Biopharma's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of COSCIENS Biopharma over the last few years. It is COSCIENS Biopharma's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in COSCIENS Biopharma's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

COSCIENS Operating Cycle Regression Statistics

Arithmetic Mean241.88
Geometric Mean170.09
Coefficient Of Variation140.54
Mean Deviation166.12
Median143.97
Standard Deviation339.94
Sample Variance115,562
Range1.5K
R-Value(0.27)
Mean Square Error114,248
R-Squared0.07
Significance0.29
Slope(18.21)
Total Sum of Squares1.8M

COSCIENS Operating Cycle History

2026 194.27
2025 236.98
2024 206.07
2023 362.81
2022 221.2
2021 171.49
2020 110.12

About COSCIENS Biopharma Financial Statements

Investors use fundamental indicators, such as COSCIENS Biopharma's Operating Cycle, to determine how well the company is positioned to perform in the future. Although COSCIENS Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Operating Cycle 236.98  194.27 

Currently Active Assets on Macroaxis

When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is there potential for Biotechnology market expansion? Will COSCIENS introduce new products? Factors like these will boost the valuation of COSCIENS Biopharma. Projected growth potential of COSCIENS fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.54)
Revenue Per Share
2.996
Quarterly Revenue Growth
0.176
Return On Assets
(0.17)
Return On Equity
(1.13)
Understanding COSCIENS Biopharma requires distinguishing between market price and book value, where the latter reflects COSCIENS's accounting equity. The concept of intrinsic value - what COSCIENS Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push COSCIENS Biopharma's price substantially above or below its fundamental value.
It's important to distinguish between COSCIENS Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding COSCIENS Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, COSCIENS Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.